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METHOD FOR INHIBITING ANGIOGENESIS 
WITH AURINTRICARBOXYLIC ACID, ITS 
ANALOGUES OR SALTS 
TECHNICAL FIELD 
This invention relates to the discovery that aurin 
tricarboxylic acid has potent anti-angiogenic properties 
and activity and thus may be used for new therapeutic 
approaches for diseases of neovascularization including 
the treatment of solid tumors, diabetic retinopathy and 
arthritis, among others. 
BACKGROUND ART 
US. Pat. No. 4,007,270 to Bernstein et al. discloses 
that aurintricarboxylic acid (ATA) and certain of its 
derivatives and salts are useful as complement inhibitors 
which play an important role as mediators in immune, 
allergic, immunochemical and immunopathological 
reactions. The patent discloses a method of inhibiting 
the complement system in blood serum subjecting the 
serum to aurintricarboxylic acid or its derivatives or 
salts and that ATA has anti-in?ammatory properties. 
US. Pat. No. 4,880,788 to Moake et al. discloses a 
method for preventing and treating thrombosis. Moake 
et al. suggest that aurintricarboxylic acid may prevent 
yon Willebrand Factor mediated aggregation or agglu 
tination of platelets and thereby prevents for formation 
of thromboemboli. 
Cushman, M. et al. “Preparation and Anti-HIV Ac 
tivities of Aurintricarboxylic Acid Fractions and Ana 
logues: Direct Correlation of Antiviral Potency with 
Molecular Weight”, J. Med. Chem, Volume 34, (1991) 
pp. 329-337, disclose that aurintricarboxylic acid 
(ATA) binds to small gpl20 in the absence of CD4 
binding and is sufficient for anti-HIV activity. 
Cushman, M. et al., “Synthesis and Anti-HIV Activi 
ties of Low Molecular Weight Aurintricarboxylic Acid 
Fragments and Related Compounds”, J. Med. Chem., 
Volume 34, (1991) pp. 337-342, disclose derivatives of 
aurintricarboxylic acid and their ability to afford pro 
tection against the cytopathogenicity of HIV-2 in MT-4 
cell and HIV-1 in CEM cells. Two derivatives of ATA 
were found to inhibit syncytium formation. In contrast 
to ATA itself, two of the derivatives of ATA were 
inactive when tested for prevention of the binding of 
the OKT4A monoclonal antibody to the CD4 receptor 
and also for the inhibition of HIV-1 reverse transcrip 
tase. It was concluded by Cushman et al. that these 
derivatives appear to act by a mechanism that is distinct 
from that of polymeric ATA. Cushman et al. do not 
disclose a method of use of aurintricarboxylic acid or its 
analogues or derivatives as an anti-angiogenic agent. 
Gonzalez, R. G. et al. “Fractionation and Structural 
Elucidation of the Active Components of Aurintricar 
boxylic Acid, a Potent Inhibitor of Protein Nucleic 
Acid Interactions”. Biochimica et Biophysica Acta, Vol 
ume 562, (1979) pp. 534-545, disclose that the triphenyl 
methane dye, aurintricarboxylic acid, is a potent inhibi 
tor of protein-nucleic acid interactions. Gonzalez et al. 
noted that the degree of inhibitory activity of the aurin 
tricarboxylic acid preparation depends on the degree of 
polymerization of the aurintricarboxylic acid polymer. 
The experimentation examined the ability of three frac 
tions of ATA to inhibit DNA-poly L-lysine complex 
formation. Two biologically relevant assays were used 
based on the binding of polyribouridylic acid to ribo 








al. publication noted that studies have eluded to the 
variable activity of commercial ATA preparations and 
that the commonly accepted structure of ATA might 
not be the true inhibitor of protein-nucleic acid interac 
tions. 
Mellon, W. S “Inhibitory Action of Aurintricarboxy 
lic Acid and Rifamycin AF/0l3 at the Polynucleotide 
Domain of 1,25-Dihydroxyvitamin D3-Receptor Com 
plexes”, Biochemical Pharmacology, Volume 33, Num 
ber 7, (1984) pp. 1047-1057, discloses that the binding of 
l,25~dihydroxyvitamin Dg-receptor complexes from 
chicken intestine to DNA-cellulose and isolated intesti 
nal nuclei is inhibited in a dose-dependent manner by 
ATA and rifamycin AF/0l3, which are known poly 
merase inhibitors. Mellon concluded that the observed 
inhibition was caused by ATA directly inhibiting the 
receptor. Mellon suggests that the receptor and polyme 
rases have corresponding properties, but states that the 
question remains whether this is an insubstantial similar 
ity or it is structurally relevant to hormone action. 
Moudgil, V. K. et al. “Modulation of DNA Binding 
of Glucocorticoid Receptor by Aurintricarboxylic 
Acid”, J. Steroid Bi0chem., Volume 23, Number 2, 
(1985) pp. 125-132, disclose that ATA is an inhibitor of 
the DNA-binding of rat liver glucocorticoid-receptor 
complex. They found that treatment with ATA did not 
appear to alter the steroid binding properties of the 
receptor or accelerate dissociation of the complex. 
Moudgil et al. concluded that ATA does not inhibit the 
process of receptor activation and that it may act via 
interaction with the DNA-binding sites at the glucocor 
ticoid-receptor. They suggest that the interaction may 
result in an alteration in the conformation of the acti 
vated receptor to a form unfavorable for optimum 
DNA-binding. They suggest that the skeletal structure 
of triphenylmethane, rather than the side chains, is the 
site of inhibitory action of ATA. Moudgil et al. reserve 
that the evidence presented in their study only indi 
rectly argues in favor of an interaction between ATA 
and the glucocorticoid-receptors and that further stud 
ies are required to con?rm the interaction. 
Nakane, H. et al. “Differential Inhibition of various 
Deoxyribonucleic Acid Polymerases by Evans Blue 
and Aurintri-carboxylic Acid”, Eur. J. Biochem, Vol 
ume 177, (1988) pp. 91-96, disclose that both Evans blue 
and ATA exhibited inhibitor effects on the in vitro 
activity of all DNA polymerases, including human 
DNA polymerases, a, B, 7-, DNA primase, calf-thymus 
terminal deoxynucleotidyltransferase, RLV reverse 
transcriptase, E. coli DNA polymerase I, and RNA 
polymerase. 
Skidmore, A. F. et al. “Characterization and Use of 
the Potent Ribonuclease Inhibitor Aurintricarboxylic 
Acid for the Isolation of RNA from Animal Tissues”, 
Biochem. J., Volume 263, (1989) pp. 73-80, disclose 
studies of ATA which yield that it is very useful as an 
RNAase inhibitor. 
Schols, D. et al., “Speci?c Interaction of Aurintricar 
boxylic Acid with the Human Immunode?ciency Vi 
rus/CD4 Cell Receptor”, Proc. Natl. Acad. Sci. USA, 
Volume 86, (May 1989) pp. 3322-3326, disclose that 
ATA is a compound that affects a rapid and selective 
modulation of CD-4 receptor expression on T4'*' cells 
without affecting the expression of other cell-surface 
markers. Schols et al. suggest that the exact mechanism 
by which ATA blocks a CD-4 receptor remains un 
known but the anionic character of ATA suggests that 
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ATA should be able to bind to lysine and/or arginine 
residues. Strony, J. et al. “Aurintricarboxylic Acid in a 
Canine Model of Coronary Artery Thrombosis”, Circu 
lation, Volume 81, Number 3, (March 1990) pp. 
1106-1114, disclose that ATA is unique in its inhibition 
of glycoprotein Ib-mediated platelet adhesion and sub 
sequent aggregation. Strony et al. suggest that platelet 
glycoprotein Ib-von Willebrand factor interactions are 
important during coronary occlusion and that ATA can 
inhibit coronary thrombosis associated with coronary 
constriction. Strony et al. do not state that the inhibition 
of coronary occlusion is due to anti-angiogenic proper 
ties of ATA. 
Benezra, M. et al. “Reversal of Basic Fibroblast 
Growth Factor-mediated Autocrine Cell Transforma 
tion by Aromatic Anionic Compounds”, Cancer Re 
search, Volume 52, (Oct. 15, 1992) pp. 5656-5662, dis 
close that ATA binds to basic ?broblast growth factor. 
Benezra et al. disclose that a common feature of com 
pounds such as ATA and other dyes is their ability to 
mimic many of the biological effects of heparin such as 
anti-coagulation, release of ECM-bound bFGF, inhibi 
tion of heparanase activity and interaction with lipopro 
tein lipase. The study suggests that the effect of ATA 
may not be due to the actual interaction with bFGF, 
suggesting that ATA may function by blocking the 
participation of bFGF in an intracellular autocrine 
pathway. 
Kan, M. et al. “An Essential Heparin-binding Do 
main in the Fibroblast Growth Factor Receptor Ki 
nase”, Science, Volume 259, (Mar. 26, 1993) pp. 
1918-1921, disclose that heparin or heparin-like heparan 
sulfate proteoglycans are necessary for activity of the 
heparin-binding ?broblast growth factor family. Hepa 
rin interacts independently of the FGF ligand with a 
speci?c sequence (K18K) in one of the immunoglobu 
lin-like loops in the extracellular domain of the FGF 
receptor tyrosine kinase transrnembrane glycoprotein. 
Kan et al. found that a synthetic peptide corresponding 
to the K18K inhibited heparin and heparin dependent 
FGF binding to the receptor. 
Bouck, N. “Tumor Angiogenesis: The Role of Onco 
genes and Tumor Suppressor Genes”, Cancer Cells, 
Volume 2, Number 6, (June 1990) pp. 179-185, discloses 
that the progressive growth of solid tumors is strictly 
dependent on their ability to attract new blood vessels 
that will supply them with oxygen and essential nutri 
ents. Angiogenesis has been shown to precede or ac 
company malignancy. The focus of Bouck’s study was 
to con?rm that suppressor gene loss can in?uence angi 
ogenesis. Bouck conjectures that molecules produced 
by normal cells that block angiogenesis may be helpful 
in combating tumor growth and the molecules pro 
duced by tumor cells that promote angiogenesis may be 
useful targets for anti-tumor drugs. 
Gagliardi, A. et a1. “Inhibition of Angiogenesis by 
Suramin”, Cancer Research, Volume 52, (Sep. 15, 1992) 
pp. 5073-5075, disclose the ability of suramin to inhibit 
anglogenesis in chick chorioallantoic membrane. Ga 
gliardi et al. disclose that suramin alone inhibited anglo 
genesis, and potentiated the activity of angiostatic ste 
roids. Weisz, P. B. et al., “Anglogenesis and Heparin 
Mimics”, Anglogenesis: Key Princ1ples—Science—Tech 
nology-Medicine, (eds. R. Steiner, P. B. Weisz & R. 
Langer), (1992) pp. 107-117, disclose that glycosami 
noglycans, such as heparin, can modulate angiogenesis 












heparin production lots and thus in glycosaminoglycans 
of different chemical structure. 
Folkman, J. et al. “Angiogenesis Inhibition and 
Tumor Regression Caused by Heparin or a Heparin 
Fragment in the Presence of Cortisone”, Science, Vol 
ume 221, (Aug. 19, 1983) pp. 719-725, disclose the in 
hibitory effect of heparin-cortisone. 
Allain et al., “Mise en evidence de l’action anti 
in?ammatoire de l’alumninon ou acide aurine tribox 
ylique”, C. R. Seances Soc. Biol. Fil, Volume 174, 
(1980) pp. 68-73, disclose that aurintricarboxylic acid 
reduces Freund adjuvant-induced arthritis and cara 
geen-induced oedemas in the paws of rats. Allain et al. 
do not disclose that aurintricarboxylic acid has anti 
angiogenic properties but disclose the use of aurintricar 
boxylic acid as an anti-in?ammatory agent for the treat 
ment of arthritis. 
DISCLOSURE OF THE INVENTION 
It is an object of the present invention to provide a 
method for use of aurintricarboxylic acid, its analogues, 
salts and derivatives as anti-angiogenic agents or inhibi 
tors of angiogenesis. 
It is another object of the present invention to pro 
vide a method for the treatment of diseases which are 
anglogenesis-dependent such as the treatment of solid 
tumors, diabetic retinopathy, arthritis, for example. 
It is another object of the present invention to pro 
vide a pharmaceutical composition for the treatment of 
diseases which are angiogenesis-dependent diseases. 
A further object of the present invention provides a 
method of inhibiting anglogenesis using a compound 
which is not mitogenic to cells of an animal. 
BRIEF DESCRIPTION OF THE DRAWING 
FIG. 1 shows the percentage of inhibition of anglo 
genesis due to increasing amounts of aurintn'carboxylic 
acid (ATA) and aurin, with and without heparin. 
DESCRIPTION OF THE INVENTION 
Anglogenesis is the formation of blood and lymph 
vessels. Angiogenesis dependent diseases include, but 
are not limited to, tumor growth and metastasis, dia 
betic retinopathy, neovascular glaucoma and rheuma 
toid arthritis. 
Thus, there is a need for experimentation and discov 
ery of compounds, pharmaceutical compositions and 
methods for the inhibition of angiogenesis. 
It has now been discovered that the aurintricarboxy 
lic acid compounds and compositions of this invention 
are useful in the inhibition of angiogenesis and thus in 
the treatment of diseases which are anglogenesis 
dependent. 
Standard angiogenesis assays are well known in the 
art. These assays include proliferation and migration 
studies using various cell lines, collagenase inhibition 
and an in vivo angiogenesis assay on chicken chorioal 
lantoic membranes (CAM) (see Auerbach, Dev. Biol. 
(1974) 41:391; and Crum, Science, Volume 230, (1985) p. 
1375). 
The chorioallantoic membrane of the chick embryo is 
often used as a semi-quantitative bioassay of angiogenic 
activity. The assay is quick and inexpensive and permits 
continuous, serial observations of changes in blood 
vessel growth. The rapid vascular growth of the CAM 
makes it an ideal model for observing modulation of 
angiogenesis, since sustained release implants contain 
ing speci?c test substances can be placed on the grow 
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ing capillary network of the CAM (see Woltering et al. 
1991. “Somatostatin analogues Inhibit Angiogenesis in 
the Chick Chorioallantoic Membrane”, Journal of Sur 
gical Research, 50: 245-251; and Oikawa et al. 1989. 
Cancer Letters, 48:157-162). The CAM assay is prefer 
entially employed for searching for anti~angiogenic 
substances. The CAM model has been used to assay 
tumor related angiogenesis. 
It is widely accepted that human and animal tumors 
can induce endothelial cell mitosis and anglogenesis, 
resulting in extensive neovascularization. Thus, angio 
genic activity is critical for tumorimplantation and 
subsequent growth. It has been shown that in the ab 
sence of neovascularization that the size of tumor grafts 
becomes limited. It is also known that neovasculariza 
tion is essential for tumor growth, development, and 
metastasis; furthermore, when angiogenesis is absent, 
tumors tend to remain dormant (see Woltering et al., 
supra). Therefore, angiogenic activity has been directly 
correlated with tumor growth. 
A variety of non-neoplastic diseases, previously 
thought to be unrelated, can be considered “angiogenic 
diseases” because they are dominated by the pathologi 
cal growth of capillary blood vessels. These diseases 
include diabetic retinopathy, arthritis, hemangiomas, 
psoriasis, and ocular neovascularization, for example. 
There seems to belittle or no biochemical difference 
between angiogenic peptides expressed by tumors and 
those expressed by normal tissues. Nor are there any 
morphological differences between the new capillaries 
that respond to a malignancy and the capillary growth 
that occurs during physiological neovascularization 
(see Folkman et al. 1987. “Angiogenic Factors”, Sci 
ence, 235: 442-447). 
As there is no qualitative difference between the 
angiogenic capabilities of nonmalignant and malignant 
diseases, results from normal and malignant vasculariza 
tion assays can be easily compared, and progress can be 
made in either area independently of the system of in 
vestigation used (see Paweletz et al. 1989. “Tumor 
related Angiogenesis”, Critical Reviews in Oncology/ 
Hematology, Volume 9, Issue 3, p. 197-198; and 
Takigawa et al. 1990. “Tumor Angiogenesis and Poly 
amines: a-Di?uoromethylornithine, and Irreversible 
Inhibitor of Ornithine Decarboxylase, Inhibits B16 
Melanoma-Induced Angiogenesis in Ovo and the Pro~ 
liferation of Vascular Endothelial Cells in vitro”, Can 
cer Research, 50: 4131-4138). 
In addition, Glaser et al. have found that cultured 
human retinal pigment epithelial cells release a sub 
stance which, when applied to the CAM, causes regres 
sion of new blood vessels and also inhibits the prolifera 
tion of bovine endothelial cells in vitro. Thus, the CAM 
assay is an acceptable assay for diabetic retinopathy 
(Glaser et al., 1983. “Retinal Pigment Epithelial Cells 
release inhibitors of neovacularization”, Ophthalmology, 
94: p. 780). 
Therefore, it is readily understood by one of ordinary 
skill in the art that an in vivo CAM assay showing the 
anti-angiogenic properties of ATA can readily be corre 
lated to human treatments of angiogenesis-dependent 
diseases, such as tumor growth, diabetic retinopathy 
and arthritis. 
Aurintricarboxylic acid (ATA) is a heterogeneous 
mixture of polymers that forms when salicylic acid is 
treated with formaldehyde, sulfuric acid and sodium 
nitrite (see Cushman, M. et al. “Preparation and Anti 











and Analogues: Direct Correlation of Antiviral Po 
tency with Molecular Weight”, J. Med. Chem., Volume 
34, (1991) pp. 329-337; Cushman, M. et al. “Synthesis 
and Anti-HIV Activities of Low Molecular Weight 
Aurintricarboxylic Acid Fragments and Related Com 
pounds”, J. Med. Chem., Volume 34, (1991) pp. 
337-342). 
Aurintricarboxylic acid is generally known to have 







The heterogeneous mixture of ATA has been shown 
to inhibit protein nucleic acid interactions (Gonzalez, R. 
G. et al. “Fractionation and Structural Elucidation of 
the Active Components of Aurintricarboxylic Acid, a 
Potent Inhibitor of Protein Nucleic Acid Interactions”, 
Biochimica et Biophysica Acta, Volume 562, (1979) pp. 
534-545); to interact with steroid receptors at the nu 
clear uptake and the nuclear binding levels (Mellon, W. 
S., “Inhibitory Action of Aurintricarboxylic Acid and 
Rifamycin AF/013 at the Polynucleotide Domain of 
1,25-Dihydroxyvitamin D3-Receptor Complexes”, Bio 
chemical Pharmacolog, Volume 33, Number 7, (1984) 
pp. 1047-1057; Moudgil, V. K. et al., “Modulation of 
DNA Binding of Glucocorticoid Receptor by Aurin 
tricarboxylic Acid”, J. Steroid Biochem., Volume 23, 
Number 2, (1985) pp. 125-132); to inhibit DNA poly 
merase (Nakane, H. et al. “Differential Inhibition of 
various Deoxyribonucleic Acid Polymerases by Evans 
Blue and Aurintri-carboxylic Acid”, Eur. J. Biochem., 
Volume 177, (1988) pp. 91-96); and to act as a RNAase 
inhibitor (Skidmore, A. F. et al. “Characterization and 
Use of the Potent Ribonuclease Inhibitor Aurintricar 
boxylic acid for the Isolation of RNA from Animal 
Tissues”, Biochem. J., Volume 263, (1989) pp. 73-80). 
ATA is a nonsulfated negatively-charged aromatic 
mixture of polymers that competes with heparin sulfate 
for binding to bFGF. ATA has been shown to reverse 
the transformed phenotype of sp bFGF transformed 
cells (cells transfected with a chimeric signal peptide 
FGF) in terms of cell proliferation rate, morphological 
appearance and adhesive properties (Benezra, M. et al. 
“Reversal of Basic Fibroblast Growth Factor-mediated 
Autocrine Cell Transformation by Aromatic Anionic 
Compounds”, Cancer Research, Volume 52, (Oct. 15, 
1992) pp. 5656-5662). The capacity of ATA to interfere 
with the bFGF autocrine loop suggests important ther 
apeutic potential in neoplastic diseases. 
ATA is also a selective marker molecule for the im 
munode?ciency virus/CD4 receptor (Schols, D. et al. 
“Speci?c Interaction of Aurintricarboxylic Acid with 
the Human Immunode?ciency Virus/ CD4 Cell Recep 




It inhibits platelet dependent thrombus formation 
(Strony, J. et a1. “Aurintricarboxylic Acid in a Canine 
Model of Coronary Artery Thrombosis”, Circulation, 
Volume 81, Number 3, (March 1990) pp. 1106-1114), 
and reverts basic ?broblast growth factor (bFGF) me 
diated autocrine cell transformation. Recent studies 
suggest that the interaction of bFGF with cell surface 
heparin sulfate is required for subsequent binding to 
high af?nity cell surface receptors and signal transduc 
tion (Benezra, M. et al. “Reversal of Basic Fibroblast 
Growth Factor-mediated Autocrine Cell Transforma 
tion by Aromatic Anionic Compounds”, Cancer Re 
search, Volume 52, (Oct. 15, 1992) pp. 5656-5662). 
Members of the FGF family are characterized by 
their high af?nity for glycosaminoglycan and heparin, 
and their high mitogenicity for mesoderm and neuroec 
toderm derived cells. Furthermore, they are among the 
most potent inducers of neovascularization (see Kan, M. 
et al., “An Essential Heparin-binding Domain in the 
Fibroblast Growth Factor Receptor Kinase”, Science, 
Volume 259, (Mar. 26, 1993) pp. 1918-1921; Ornitz, D. 
M. et a1. “Heparin is Required for Cell-free Binding of 
basic Fibroblast Growth Factor to a Soluble Receptor 
and for Mitogenesis in Whole Cells”, Molecular and 
Cellular Biolog, Volume 12, (January 1992) pp. 
240-247; Klagsbrun, M. et al. “MINIREVIEW: A Dual 
Receptor System is Required for Basic Fibroblast 
Growth Factor Activity”, Cell, pp. 229-231; Risau, W., 
“Angiogenic Growth Factors”, Progress in Growth Fac 
tor Research, Volume 2, (1990) pp. 71-79; Bouck, N., 
“Tumor Angiogenesis: The Role of Oncogenes and 
Tumor Suppressor Genes”, Cancer Cells, Volume 2, 
Number 6, (June 1990) pp. 179-185). 
A series of negatively charged aromatic compounds 
which mimic many of the effects of heparin, including 
suramin and ATA, compete with FGF binding with 
heparin sulfate on the cell surface (Benezra, M. et al., 
“Reversal of Basic Fibroblast Growth Factor-mediated 
Autocrine Cell Transformation by Aromatic Anionic 
Compounds”, Cancer Research, Volume 52, (Oct. 15, 
1992) pp. 5656-5662). The ability of solid tumors to 
grow to a clinically signi?cant size is dependent on 
angiogenesis (Kan, M. et al. “An Essential Heparin 
binding Domain in the Fibroblast Growth Factor Re 
ceptor Kinase”, Science, Volume 259, (Mar. 26, 1993) 
pp. 1918-1921. Stimulation of bFGF and the vasculo 
tropin/endothelial cell growth factor is a critical event 
in angiogenesis (Folkman, J. et al. “Anglogenesis Inhi 
bition and Tumor Regression Caused by Heparin or a 
Heparin Fragment in the Presence of Cortisone”, Sci 
ence, Volume 221, (Aug. 19, 1983) pp. 719-725). 
Growth factors have been shown to be displaced 
from their receptors by suramin (Benezra, M. et a1. 
“Reversal of Basic Fibroblast Growth Factor-mediated 
Autocrine Cell Transformation by Aromatic Anionic 
Compounds”, Cancer Research, Volume 52, (Oct. 15, 
1992) pp. 5656-5662), and it has been recently shown 
that suramin is a potent inhibitor of angiogenesis (Ga 
gliardi, A. et al., “Inhibition of Angiogenesis by Sura 
min”, Cancer Research, Volume 52, (Sep. 15, 1992) pp. 
5073-5075). 
ATA may mimic many of the actions of heparin with 
out being mitogenic to endothelial cells (W eisz, P. B. et 
a1. “Anglogenesis and Heparin Mimics”, Angiogenesis: 
Key Principles—Science—Technology-Medicine, (eds. 
R. Steiner, P. B. Weisz & R. Langer), (1992) pp. 
107-117). Folkman et a1. (Folkman, J. et a1. “Angiogen 











rin or a Heparin Fragment in the Presence of Corti 
sone”, Science, Volume 221, (Aug. 19, 1983) pp. 
719-725) showed that heparin and heparin fragments 
without anticoagulant activity inhibited angiogenesis in 
the presence of cortisol, l7a-hydroxyprogesteroneand 
tetrahydrocortisol. 
Experimentation was performed to determine the 
ability of aurintricarboxylic acid, its salts, derivatives 
and analogues to inhibit anglogenesis in the chick cho 
rioallantoic membrane. 
The example set forth below demonstrates the dose 
dependent inhibition of angiogenesis by ATA. In addi 
tion, the interaction of ATA with heparin and angio 
static steroids is described. 
EXAMPLE 1 
Materials and Methods 
Aurintricarboxylic acid trisodium salt and aurin were 
obtained from Aldrich Chemical Company, Milwau 
kee, Wis. Procedures for the synthesis of aurintricar 
boxylic acid are reported (see Heisig, G. B. and Lauer, 
W. M. Org. Syn., Volume 9, (1928) p. 54-55.) Aurin 
tricarboxylic acid was also obtainable from Fischer 
Scienti?c Co., Sigma Chemical Company, and Mallink 
rodt Chemical Co. (See Gonzalez, R. G. et al. “Frac 
tionation and Structural Elucidation of the Active 
Components of Aurintricarboxylic Acid, a Potent In 
hibitor of Protein Nucleic Acid Interactions”, Bio 
chimica et Biophysica Acta, Volume 562, (1979) pp. 
534-545). 
Heparin sodium USP (PM-20487, activity 171 U/mg) 
was a gift from Dr. Judah Folkman, Boston, Mass. The 
steroids were obtained from Sigma Chemical Co., St. 
Louis, M0. or Steraloids, Inc., Wilton, NH. All other 
chemicals were of reagent grade. Fertilized eggs (SPF 
grade) were obtained from Sunrise Farms (Catskill, 
NY). 
The ability of suramin compounds to inhibit angio 
genesis was determined as previously described (Ga 
gliardi, A. et al., “Inhibition of Angiogenesis by Sura 
min,”, Cancer Research, Volume 52, (1992) pp. 
5073-5075), using a modi?cation of the chick chorioal 
lantoic membrane (CAM) assay (Crum, R. et al., “A 
New Class of Steroids Inhibits Angiogenesis in the 
Presence of Heparin or a Heparin Fragment”, Science 
(Washington, DC), Volume 230, (1985) pp. 
1375-1378). The eggs were cracked on day 3 and the 
embryos placed in petri dishes in a humidi?ed CO2 
incubator (3% CO2/air) at 37° C. Each compound or 
combination of compounds to be tested were dissolved 
in methylcellulose (0.45%) and the solution (10 pl) was 
air-dried on a Te?on-coated metal tray. The methylcel 
lulose disk was implanted on the outer third of a day 6 
CAM where capillaries were still growing. The disk 
alone and cortisol-Zl-phosphate (100 pg) plus heparin 
(80 pg) were used as negative and positive controls, 
respectively. The zone around the disk was examined 48 
hours after implantation and inhibition of anglogenesis 
was indicated by an avascular zone of 24 mm diameter 
around the disk. At least 20 embryos were measured for 
each compound or combination of compounds. The 
results were expressed as the percentage of embryos 
which showed inhibition of angiogenesis. 
The vessels of the CAM preparation grew rapidly 
until day 10, after which endothelial proliferation de 
crease sharply (Ausprunk, D. R. et al., Developmental 
Biology, Volume 38, (1974) p. 237; Folkman, J. et al. 
“Angiogenesis Inhibition and Tumor Regression 
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Caused by Heparin or a Heparin Fragment in the Pres 
ence of Cortisone”, Science, Volume 221, (1983) pp. 
719-725). The effects of drug treatment on established 
vessels with low angiogenic activity were also deter 
mined by implanting the compound or combination of 
compounds to be tested on day 13 and determining the 
percentage of embryos showing inhibition of angiogen 
esis on day 15 (late implants). 
The effects of increasing amounts of ATA, aurin and 
aurin plus heparin on the inhibition of angiogenesis are 
shown in Table 1 and FIG. 1 below. ATA clearly inhib 
ited anglogenesis when 4 pg were added to the disk 
(35% inhibition), and the inhibition increased in a dose 
related manner to 91% when 32 pg of ATA were 
added. On the other hand, aurin showed much lower 
activity with 35% inhibition when 20 pg (molar equiva 
lent to 32 pg of ATA) were added to the disk. 
The angiostatic activity by ATA was reduced in the 
presence of 80 pg of heparin. This inhibition of the 
angiostatic activity of ATA was partially overcome by 
increasing the concentration of ATA in the disk (Table 
1, FIG. 1). On the other hand, the angiostatic activity 
by aurin was not significantly changed in the presence 
of heparin (Table 1, FIG. 1 below). 
Table 2 below shows the percentage inhibition of 
anglogenesis by several steroids either alone or in the 
presence of heparin or ATA. None of the steroids stud 
ied showed signi?cant inhibitory activity alone under 
the condition of the CAM assay. All the steroids exam 
ined (cortisol-Zl-phosphate, l7-a-hydroxyprogester 
one, tetrahydrocortexolone and tetrahydrocortisol) 
exhibited signi?cant inhibition of angiogenesis in the 
presence of 8 pg of ATA. 
Table 3 below shows the results for disks implanted 
on day 13. ATA clearly exhibited angiostatic activity 
with 85% inhibition at a concentration of 32 pg. Aurin 
alone showed much less angiostatic activity with 10% 
inhibition at an equivalent molar concentration. Only 
ATA and suramin exhibited angiostatic activity in both 
the early and late CAM preparation. Neither cortisol 
2l-phosphate, tetrahydrocortisol, tetrahydrocortexo 
lone nor l7a-hydroxyprogesterone in the presence of 
heparin nor tamoxifen, clomifene and ICI 182, 780 alone 
showed angiostatic activity in the late CAM. 
The results of these experiments clearly show that 
ATA is a potent inhibitor of anglogenesis in the CAM. 
Furthermore, the inhibition of angiogenesis is dose de 
pendent, increasing from 25% inhibition with 4 pg of 
ATA to 91% inhibition at 32 pg. The angiostatic activ 
ity of ATA is not dependent on the presence of heparin. 
Thus, ATA seems to be similar to, but more potent, 
than suramin in its anti-angiogenic activity (Gagliardi, 
A. et al., “Inhibition of Angiogenesis by Suramin”, 
Cancer Research, Volume 52, (Sep. 15, 1992) pp. 
5073-5075). 
An additional ?nding from the above example is the 
antagonism between ATA and heparin. The multiple 
sulfate groups on heparin complex with molecules con 
taining cationic centers, such as cationic dyes and pep 
tides/proteins with neighboring basic amino acid resi 
dues (including FGF) (W eisz, P. B. et al., “Anglogene 
sis and Heparin Mimics”, Angiogenesis: Key Princi 
ples—Science—TechnoIogy-—Medicine, (eds. R. Steiner, 
P. B. Weisz & R. Langer), (1992) pp. 107-117). In angio 
genesis and endothelial cell growth promotion, heparin 
like substances complex to bFGF, the cell surface and 












Aurintricarboxylic acid showed potent anti-angio 
genic activity in a dose related manner. In the presence 
of heparin, the anti-angiogenic activity of aurintricar 
boxylic acid was decreased. Aurintricarboxylic acid 
also potentiated the activity of the angiostatic steroids 
such as cortisol-Zl-phosphate, 17-a-hydroxyprogester 
one, tetrahydrocortexolone and tetrahydrocortisol. 
The above results indicate that ATA may effectively 
replace heparin as an activator of angiostatic steroids 
(Table 2 below). We have previously shown (Gagliardi, 
A. et al., “Inhibition of Angiogenesis by Suramin”, 
Cancer Research, Volume 52, (1992) pp. 5073-5075) that 
suramin can inhibit angiogenesis in the CAM prepara 
tion. In addition, the anti-angiogenic activity of suramin 
is antagonized by heparin. ATA, at concentrations 10 
fold lower than suramin, expressed a similar inhibitory 
activity on angiogenesis. 
The structures of ATA, suramin and heparin show 
important differences in chemical structure. The most 
notable difference being that the major polyanionic 
group in heparin and suramin is sulfonate, whereas 
ATA contains carboxylate groups. Both suramin and 
ATA contain aromatic rings lined via enzyme resistant 
methylene groups, while heparin has a sugar backbone. 
The molecular weights of these compounds are vastly 
different. The heparin used in these studies had a molec 
ular weight of 20,487, suramin had a molecular weight 
of 1,430 and ATA (although being a heterogenous mix 
ture) had an estimated molecular weight of around 
3,000—5,000 (Cushman, M. et al., “preparation and Anti 
HIV activities of aurintricarboxylic acid fractions and 
analogues: direct correlation of antiviral potency with 
molecular weight”, J. Med. Chem., Volume 34, (1991) 
pp. 329-337). The presence of the carboxylic groups on 
ATA is considered to be important for angiostatic ac 
tivity because aurin, a chemically related compound 
without the tricarboxylic residues, exhibits low anti 
angiogenic activity. 7 
The inhibitory effects of ATA and suramin in the 
13-day CAM preparation when FGF level in the CAM 
?uid is very low suggest that these compounds may 
affect blood vessels by mechanisms other than blocking 
bFGF action on endothelial cell growth. 
These novel ?ndings suggest that aurintricarboxylic 
acid provides the basis for important new therapeutic 
approaches for diseases of neovascularization. 
Thus, the invention relates to a method comprising 
inhibiting angiogenesis by administering an effective 
amount of aurintricarboxylic acid, its analogues, deriva 
tives or salts. The invention comprises a method for the 
treatment of angiogenesis-dependent diseases by admin 
istering an effective amount of aurintricarboxylic acid, 
its analogues, derivatives or salts to a patient. Angiogen 
esis dependent diseases include, but are not limited to 
diabetic retinopathy, arthritis, tumor growth and metas 
tasis and neovascular glaucoma. Treatments may in 
clude an effective amount which comprises about 10 
mg/kg/ day of aurintricarboxylic acid. 
In an alternative embodiment, the method for inhibit 
ing angiogenesis includes administering an effective 
amount of a composition comprising aurintricarboxylic 
acid, its analogues, derivatives or salts and asteroid 
composition to an animal. The steroid composition may 
be selected from the group consisting of cortisol-21 
phosphate, l7-a-hydroxyprogesterone, tetrahydrocor 
texolone and tetrahydrocortisol or mixtures thereof. 
The invention includes a pharmaceutical composition 
for the inhibition of angiogenesis comprising an anglo~ 
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genesis inhibiting amount of aurintricarboxylic acid and 
a steroid composition selected from the group consist 
ing of cortisol-Zl-phosphate, l7-a-hydroxyprogester 
one, tetrahydrocortexolone and tetrahydrocortisol. 
Compounds of the present invention have anti‘angio 
genic properties in animals. Compounds of the present 
invention and compositions which are shown to have 
physiological effects of inhibiting angiogenesis ?nd use 
in numerous therapeutical applications, such as the 
treatment of angiogenesis~dependent diseases, including 
diabetic retinopathy, arthritis, tumor growth and metas 
tasis and neovascular glaucoma. 
Therapeutic compositions comprise an effective 
amount of the compounds of the invention including 
non-toxic addition salts. Such compositions can also be 
provided together with physiologically tolerable liquid, 
gel or solid diluents, adjuvants and excipients. 
These compositions can be administered to animals 
for veterinary use, such as with domestic animals and 
clinical use in humans in a manner similar to other thera 
peutic agents. In general, the dosage required for thera 
peutic efficacy will range from about 1 pg to 300 
mg/kg, preferably 10 pg to 30 mg/kg of the host body 
weight, and more preferably about 6.7 mg/kg or 10.0 
mg/kg of host body weight of aurintricarboxylic acid. 
Alternatively, dosages within these ranges can be ad 
ministered by constant infusion over an extended period 
of time, usually exceeding 24 hours, until the desired 
therapeutic bene?ts have been obtained. The chemical 
structure suggests that this compound will be ef?ciently 
absorbed from the gut. One may also deliver this mate 
rial directly into the eye using implants of via an implant 
in or on the skin. 
Typically such compositions are prepared as injecta 
bles, either as liquid solutions or suspensions; solid 
forms suitable for solution in, or suspension in, liquid 
prior to injection may also be prepared. The prepara 
tion may also be emulsi?ed. The active ingredient is 
often mixed with diluents or excipients which are physi 
ologically tolerable and compatible with the active 
ingredient. Suitable diluents and excipients are, for ex 
ample, water, saline, dextrose, glycerol, or the like, and 
combinations thereof. In addition, if desired, the com 
positions may contain minor amounts of auxiliary sub 
stances such as wetting or emulsifying agents, stabiliz 
ing agents, or pH buffering agents, and the like. 
The compositions are conventionally administered by 
injection, either subcutaneously or intravenously. Addi 
tional formulations which are suitable for other modes 
of administration include, suppositories, intranasal aero 
sol, and in some cases, oral formulations. For supposito 
ries, traditional binders and excipients may include, for 
example, polyalkylene glycols or triglycerides: such 
suppositories may be formed from mixtures containing 
the active ingredient in the range of 0.5 to 10%, prefera 
bly 1-2%. Oral formulations include such normally 
employed excipients as, for example, pharmaceutical 
grades of mannitol, lactose, starch, magnesium stearate, 
sodium saccharine, cellulose, magnesium carbonate, 
and other conventional additives. These compositions 
take the form of solutions, suspensions, tablets, pills, 
capsules, sustained release formulations or powders and 
contain 10% to 90% of the active ingredient, preferably 
25% to 70%. These oral formulations are designed to 
protect the activity of the'aurintricarboxylic acid com 










The aurintricarboxylic acid compositions of the in 
vention can be formulated into the compositions as 
neutral or salt forms. Pharmaceutically acceptable non 
toxic salts include the acid addition salts, for example, 
hydrochloric or phosphoric acids or such organic acids 
as ascetic, oxalic, tartaric, mandelic, etc. Salts formed 
with free carboxyl groups may be derived from inor 
ganic bases such as, for example, sodium, potassium, 
ammonium, calcium or ferric hydroxides. Tissue cul 
ture experiments show that ATA binds basic ?broblast 
growth factor at pH 6.5-7.5. (Benezra, M. et al., “Re 
versal of basic ?broblast growth-mediated autocrine 
cell transformation by aromatic anionic compounds”, 
Cancer Research, Volume 52, (1992) pp. 5656-5662. 
Thus it is preferred that pharmaceutical compositions of 
the invention have a pH of about 6.5—7.5. 
TABLE 1 
Percentage of inhibition of angiogenesis for 
different amounts of Aurintricarboxylic acid (ATA) and Aurin 
alone and in combination with heparin. The number of 
embryos showing inhibition/total embryos evaluated (+/total) 
and the percentage showing inhibition (% of inhibition) are 
shown. 
EMBRYOS % of 
COMPOUND (+/total) Inhibition 
Disk only 0/ 25 0 
2 pg ATA 3/22 14 
4 pg ATA 5/20 25 
8 pg ATA 8/21 38 
16 pg ATA 12/20 60 
32 pg ATA 20/ 22 91 
64 pg ATA 23/23 100 
1.25 pg Aurin 0/20 0 
2.50 pg Aurin 0/24 0 
5.00 pg Aurin 1/23 4 
10.00 pg Aurin 2/21 10 
20.00 pg Aurin 10/29 35 
pg ATA 
2 + 80 pg heparin 0/22 0 
4 + 80 pg heparin 0/21 0 
8 + 80 pg heparin 3/20 15 
16 + 80 pg heparin 8/20 40 
32 + 80 pg heparin 12/20 60 
64 + 80 pg heparin 17/21 81 
pg Aurin 
1.25 + 80 pg heparin 0/22 0 
2.50 + 80 pg heparin 0/20 0 
5.00 + 80 pg heparin 0/22 0 
10.00 + 80 pg heparin 1/20 5 
20.00 + 80 pg heparin 4/20 20 
TABLE 2 
Percentage of Inhibition of Angiogenesis for Angiostatic 
Steroids alone or in the presence of 100 pg of heparin or 
increasing amounts of aurintricarboxylic acid (ATA). The number 
of embryos showing inhibition/total embryos evaluated (+/total) 
and the percentage showing inhibition (% of inhibition) are shown. 
EMBRYOS % of 
COMPOUND (+/total) Inhibition 
100 pg cortisol-Zl-phosphate only 8/29 26 
+2 pg ATA - 8/22 36 
+4 pg ATA 10/20 50 
+8 pg ATA 1.8/21 86 
+16 pg ATA 20/21 95 
+32 pg ATA 23/23 100 
+80 pg heparin 27/41 66 
100 pg l7a-hydroxyprogesterone 0/54 0 
only 
+2 pg ATA 11/23 48 
+4 pg ATA 16/20 69 
+8 pg ATA 22/23 95 
+80 pg heparin 26/58 45 
100 pg tetrahydroeortisol only 0/53 0 
+2 pg ATA 8/22 36 
+4 pg ATA 13/22 59 
5,434,185 
13 14 
TABLE 2-continued TABLE 3'contmued 
Percentage of Inhibition of Angiogenesis for Several 
Percentage of Inhibition of Angiogenesis for Angiostatic Compounds Implanted on the Late CAM (Day 13) and Early 
- - - CAM (Day 6). The number of embryos showing inhibition/total 
Stero1ds alone or in the presence of 100 pg of heparin or 5 embryos evaluated (+/t°ta1) and the percentage showing 
increasing amounts of aurintricarboxylic acid (ATA). The number inhibition (% of inhibition) are shown. 
of embryos showing inhibition/total embryos evaluated (+/total) LATE CAM EARLY CAM 
and the percerlage showing inhibition (% of inhibition) are shown. 133$‘ EMBRYOS I315; EMBRYOS 
1- _ 
EMBRYOS % of 10 COMPOUND tion (+/tota.l) tion (+/total) 
COMPOUND (+/tota1) Inhibition (100 as) + 
heparin (100 pg) 
+8 pg ATA 22/25 88 Clomiphene 0 (0/18) 59 (13/22) . 
_ (100 111;) 
+80 “g hepan“ 17/38 45 Tamoxifen 0 (0/22) 61 (25/40) 
100 pg medroxyprogesterone acetate 0/59 0 15 (100 pg) 1 
(m1 1c1 182,780 0 (0/19) 20 (24/30) 
y Y (100 Mg) 
+2 pg ATA 9/21 43 Suramin (100 pg) 74 (26/35) 58 (15/26) 
ATA (32 pg) 85 (17/20) 91 (20/22) 
+4 "g ATA 13/23 56 Aurin (10 pg) 10 (2/20) 35 (10/29) 
+3 pg ATA 14/20 70 20 
80 h ' 0/24 0 . . . . 
+ “g epam Although the foregoing invention has been descnbed 
80 pg heparin only 0/23 in some detail by way of illustration and example for 
purposes of clarity and understanding, it will be obvious 
that certain changes and modi?cations may be practiced 
TABLE 3 25 within the scope of the appended claims. 
We claim: 
1. A method for inhibiting angiogenesis in an animal 
comprising administering an effective amount to inhibit 
Percentage of Inhibition of Angiogenesis for Several 
Compounds Implanted on the Late CAM (Day 13) and Early 
CAM (Day 6) The number °f embry“ sh°wing inhibi?W/mal anglogenesis of aurintricarboxylic acid, its analogues, 01' 
embryos evaluated (+/total) and the percentage showing 30 salts to said animal. 
inhibition (% ofinhjbition) are Shown 2. A method according to claim 1, wherein said ani 
mal is a mammal or bird. 
LATE CAM EARLY CAM 3. A method according to claim 1, wherein said effec 
% of % 0f tive amount comprises about 10 mg/kg body weight of 
Inhibi~ EMBRYOS Inhibi- EMBRYOS 35 the host of aurintricarboxylic acid. 
COMPOUND tion (+/total) tion (+ howl) _4. A method according to cla1m 1, wherein sald aurm 
tricarboxyllc acid has a molecular weight of about 3000 
Disk only 0 (0/25) 0 (0/23) to 5000‘ 
cortisol-2l-PO4 5 (V18) 66 (27/41) * * * * * 
4O 
45 
5O 
55 
60 
